Manumycin A inhibits triple-negative breast cancer growth through LC3-mediated cytoplasmic vacuolation death

Cell Death and Disease

Volumn 4, Issue 1, 2013, Pages

  Singha, P K ^a   Pandeswara, S ^a   Venkatachalam, M A ^a   Saikumar, P ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

breast cancer; cell death; cytoplasmic vacuolation; ER stress; LC3; manumycin A; p62

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; DACTINOMYCIN; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; MANUMYCIN A; MICROTUBULE ASSOCIATED PROTEIN 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN P62; UBIQUITINATED PROTEIN; UNCLASSIFIED DRUG; AMIDE; ANTIINFECTIVE AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DDIT3 PROTEIN, HUMAN; FARNESYL TRANS TRANSFERASE; HEAT SHOCK PROTEIN; LIGHT CHAIN 3, HUMAN; MANUMYCIN; MICROTUBULE ASSOCIATED PROTEIN; MOLECULAR CHAPERONE GRP78; P62 PROTEIN, HUMAN; POLYENE; PTEN PROTEIN, HUMAN; RNA BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DEATH; CELL ORGANELLE; CELL VACUOLE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; UBIQUITINATION; ANIMAL; APOPTOSIS; BREAST TUMOR; CELL LINE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; XENOGRAFT;

ANIMALS; ANTI-BACTERIAL AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG RESISTANCE, NEOPLASM; ENDOPLASMIC RETICULUM STRESS; EPITHELIAL CELLS; FARNESYLTRANSTRANSFERASE; FEMALE; HEAT-SHOCK PROTEINS; HUMANS; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; POLYENES; POLYUNSATURATED ALKAMIDES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RNA-BINDING PROTEINS; TRANSCRIPTION FACTOR CHOP; TRANSPLANTATION, HETEROLOGOUS; UBIQUITINATION;

MLCS; MLOWN;

EID: 84872188814     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.192     Document Type: Article

References (42)

1. Sperandio S, Poksay K, de Belle I, Lafuente MJ, Liu B, Nasir J et al. Paraptosis: mediation by MAP kinases and inhibition by AIP-1/Alix. Cell Death Differ 2004; 11: 1066-1075. (Pubitemid 39341632)
2. Broker LE, Kruyt FA, Giaccone G. Cell death independent of caspases: a review. Clin Cancer Res 2005; 11: 3155-3162. (Pubitemid 40627860)
3. Saikumar P, Dong Z, Mikhailov V, Denton M, Weinberg JM, Venkatachalam MA. Apoptosis: definition, mechanisms, and relevance to disease. Am J Med 1999; 107: 489-506. (Pubitemid 29528339)
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
6. Wang Y, Li X, Wang L, Ding P, Zhang Y, Han W et al. An alternative form of paraptosis-like cell death, triggered by TAJ/TROY and enhanced by PDCD5 overexpression. J Cell Sci 2004; 117(Pt 8): 1525-1532. (Pubitemid 38559827)
7. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108: 153-164. (Pubitemid 34161136)
8. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874. (Pubitemid 32878711)
9. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005; 205: 275-292. (Pubitemid 40227997)
10. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003; 22: 7414-7430. (Pubitemid 37487167)
11. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 1999; 11: 68-75. (Pubitemid 29082059)
12. Bursch W, Ellinger A, Gerner C, Frohwein U, Schulte-Hermann R. Programmed cell death (PCD). Apoptosis, autophagic PCD, or others? Ann N Y Acad Sci 2000; 926: 1-12.
13. Lockshin RA, Zakeri Z. Apoptosis, autophagy, and more. Int J Biochem Cell Biol 2004; 36: 2405-2419. (Pubitemid 39119755)
14. Gozuacik D, Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 2004; 23: 2891-2906. (Pubitemid 38638851)
15. Sperandio S, de Belle I, Bredesen DE. An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci USA 2000; 97: 14376-14381. (Pubitemid 32016583)
16. Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 1995; 146: 3-15.
17. Trump BF, Berezesky IK, Chang SH, Phelps PC. The pathways of cell death: oncosis, apoptosis, and necrosis. Toxicol Pathol 1997; 25: 82-88. (Pubitemid 27100564)
18. Suarez Y, Gonzalez L, Cuadrado A, Berciano M, Lafarga M, Munoz A. Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol Cancer Ther 2003; 2: 863-872.
19. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1: 112-119.
20. Han W, Li L, Qiu S, Lu Q, Pan Q, Gu Y et al. Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther 2007; 6: 1641-1649. (Pubitemid 46954031)
21. Overholtzer M, Mailleux AA, Mouneimne G, Normand G, Schnitt SJ, King RW et al. A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion. Cell 2007; 131: 966-979. (Pubitemid 350138090)
22. Syntichaki P, Tavernarakis N. Death by necrosis. Uncontrollable catastrophe, or is there order behind the chaos? EMBO Rep 2002; 3: 604-609.
23. Edinger AL, Thompson CB. Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 2004; 16: 663-669. (Pubitemid 39463117)
24. Kar R, Singha PK, Venkatachalam MA, Saikumar P. A novel role for MAP1 LC3 in nonautophagic cytoplasmic vacuolation death of cancer cells. Oncogene 2009; 28: 2556-2568.
25. Hara M, Akasaka K, Akinaga S, Okabe M, Nakano H, Gomez R et al. Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc Natl Acad Sci USA 1993; 90: 2281-2285. (Pubitemid 23078610)
26. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11: 761-774.
27. Ahearn IM, Haigis K, Bar-Sagi D, Philips MR. Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Bio 2012; 13: 39-51.
28. Servais P, Gulbis B, Fokan D, Galand P. Effects of the farnesyltransferase inhibitor UCF- 1C/manumycin on growth and p21-ras post-translational processing in NIH3T3 cells. Int J Cancer 1998; 76: 601-608. (Pubitemid 28228007)
29. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A et al. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 1995; 55: 5302-5309.
30. Wu WK, Coffelt SB, Cho CH, Wang XJ, Lee CW, Chan FK et al. The autophagic paradox in cancer therapy. Oncogene 2012; 31: 939-953.
31. Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtininduced cell death. J Cell Biol 2005; 171: 603-614. (Pubitemid 41668720)
32. Pursiheimo JP, Rantanen K, Heikkinen PT, Johansen T, Jaakkola PM. Hypoxia-Activated autophagy accelerates degradation of SQSTM1/p62. Oncogene 2009; 28: 334-344.
33. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 2007; 282: 24131-24145. (Pubitemid 47328003)
34. Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009; 137: 1062-1075.
35. Shen S, Kepp O, Michaud M, Martins I, Minoux H, Metivier D et al. Association and dissociation of autophagy, apoptosis and necrosis by systematic chemical study. Oncogene 2011; 30: 4544-4556.
36. Canu N, Barbato C, Ciotti MT, Serafino A, Dus L, Calissano P. Proteasome involvement and accumulation of ubiquitinated proteins in cerebellar granule neurons undergoing apoptosis. J Neurosci 2000; 20: 589-599. (Pubitemid 30225561)
37. Xu G, Pan J, Martin C, Yeung SC. Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab 2001; 86: 1769-1777. (Pubitemid 32374936)
38. Yeung SC, Xu G, Pan J, Christgen M, Bamiagis A. Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res 2000; 60: 650-656. (Pubitemid 30094563)
39. Di Paolo A, Danesi R, Nardini D, Bocci G, Innocenti F, Fogli S et al. Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells. Br J Cancer 2000; 82: 905-912. (Pubitemid 30085245)
40. Nagase T, Kawata S, Tamura S, Matsuda Y, Inui Y, Yamasaki E et al. Inhibition of cell growth of human hepatoma cell line (Hep G2) by a farnesyl protein transferase inhibitor: a preferential suppression of ras farnesylation. Int J Cancer 1996; 65: 620-626. (Pubitemid 26092291)
41. Ito T, Kawata S, Tamura S, Igura T, Nagase T, Miyagawa JI et al. Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl:protein transferase inhibitor. Jpn J Cancer Res 1996; 87: 113-116. (Pubitemid 26099483)
42. Singha PK, Yeh IT, Venkatachalam MA, Saikumar P. Transforming growth factor-beta (TGF-beta)-inducible gene TMEPAI converts TGF-beta from a tumor suppressor to a tumor promoter in breast cancer. Cancer Res 2010; 70: 6377-6383.